secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001104659-24-029057
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports $485M cash, AMTAGVI launch ongoing; partial clinical hold on lung TIL trial
--------------------------------------------------------------------------------

- Cash position ~$485M as of 2/22/24, including $197.1M from Feb 2024 equity offering.
- AMTAGVI (lifileucel) approved for advanced melanoma; 30 active ATCs at launch, targeting ~50 within 90 days.
- FDA placed partial clinical hold on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused.
- Phase 3 TILVANCE-301 frontline melanoma trial randomized first patient in 2Q23.
- Proleukin acquired for £167.7M upfront; global rights secured for IL-2 supply in AMTAGVI regimen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924029057/0001104659-24-029057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924029057/tm247560d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer